tailieunhanh - báo cáo hóa học:" How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure"

Tuyển tập các báo cáo nghiên cứu về hóa học được đăng trên tạp chí hóa học đề tài : How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure | BioMed Central Health and Quality of Life Outcomes Open Access How a well-grounded minimal important difference can enhance transparency of labelling claims and improve interpretation of a patient reported outcome measure Jan L Brozek1 2 Gordon H Guyatt3 4 and Holger J Schunemann 3 5 Address Department of Medicine Jagiellonian University School of Medicine Krakow Poland 2Polish Institute for Evidence Based Medicine Krakow Poland 3CLARITY Research Group Department of Clinical Epidemiology and Biostatistics McMaster University Hamilton Ontario Canada 4Department of Medicine McMaster University Hamilton Ontario Canada and 5Division of Clinical Research Development and Information Translation INFORMA CLARITY Research Group Department of Epidemiology Istituto Regina Elena Italian National Cancer Institute Via Elio Chianesi 53 00144 Rome Italy Email Jan L Brozek - brozek@ Gordon H Guyatt - guyatt@ Holger J Schunemann - schuneh@ Corresponding author Published 27 September 2006 Received 22 September 2006 .A. J . .mz. A. AAAAAA A n Jm I A- - TTir A ZA Accepted 27 September 2006 Health and Quality of Life Outcomes 2006 4 69 doi 1477-7525-4-69 This article is available from http content 4 1 69 2006 Brozek et al licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License http licenses by which permits unrestricted use distribution and reproduction in any medium provided the original work is properly cited. Abstract__ The evaluation and use of patient reported outcome PRO measures requires detailed understanding of the meaning of the outcome of interest. The Food and Drug Administration FDA recently presented its draft guidance and view on the use of PRO measures as endpoints in clinical trials. One section of the guidance document specifically .